Potential immunophenotypic targets for pediatric LSCs have largely been explored in the context of comparing expression levels of published adult LSC markers in pediatric HSCs from healthy controls to CD34+CD38- populations from AML samples. This evidence concerns the gene CD38 and acute myeloid leukemia.